Amylyx Pharmaceuticals, Inc. (AMLX) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
12/38
1.6 / 5 stars
All 38 Win/Lose results and 82 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 7 losses, 2 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinAMLX / S&P 29.21% / 15.20% |
No dataAMLX / S&P / 15.00% |
LoseAMLX / S&P -43.37% / 50.40% |
| 2026-Q11/2 |
WinAMLX / S&P 15.07% / -4.33% |
No dataAMLX / S&P / 11.30% |
LoseAMLX / S&P -52.26% / 27.70% |
| 2025-Q40/3 |
LoseAMLX / S&P -11.11% / 2.65% |
LoseAMLX / S&P -100.00% / 9.00% |
LoseAMLX / S&P -65.46% / 13.40% |
| 2025-Q31/3 |
WinAMLX / S&P 112.01% / 8.12% |
LoseAMLX / S&P -100.34% / 4.61% |
LoseAMLX / S&P -53.14% / 13.45% |
| 2025-Q21/3 |
WinAMLX / S&P 81.07% / 10.94% |
LoseAMLX / S&P -100.08% / 4.83% |
LoseAMLX / S&P 1.63% / 10.63% |
| 2025-Q11/3 |
LoseAMLX / S&P -6.35% / -4.27% |
LoseAMLX / S&P -100.32% / 4.98% |
WinAMLX / S&P 189.72% / 10.57% |
| 2024-Q41/3 |
WinAMLX / S&P 16.67% / 2.41% |
LoseAMLX / S&P -77.06% / 5.25% |
LoseAMLX / S&P -732.86% / 6.15% |
| 2024-Q31/3 |
WinAMLX / S&P 70.53% / 5.89% |
LoseAMLX / S&P -33.22% / 5.89% |
LoseAMLX / S&P -38300.00% / 6.11% |
| 2024-Q22/3 |
LoseAMLX / S&P -33.10% / 4.28% |
WinAMLX / S&P 55.71% / 5.38% |
WinAMLX / S&P 102.48% / 5.12% |
| 2024-Q10/2 |
LoseAMLX / S&P -80.71% / 10.56% |
No dataAMLX / S&P / 5.71% |
LoseAMLX / S&P -56.33% / 5.59% |
| 2023-Q40/2 |
LoseAMLX / S&P -19.61% / 11.69% |
No dataAMLX / S&P / 6.81% |
LoseAMLX / S&P -120.59% / 7.78% |
| 2023-Q30/2 |
LoseAMLX / S&P -15.11% / -3.27% |
No dataAMLX / S&P / 7.52% |
LoseAMLX / S&P -100.14% / -5.03% |
| 2023-Q20/2 |
LoseAMLX / S&P -26.48% / 8.74% |
No dataAMLX / S&P / 9.50% |
LoseAMLX / S&P -87.17% / -8.57% |
| 2023-Q10/2 |
LoseAMLX / S&P -20.60% / 7.50% |
No dataAMLX / S&P / 10.77% |
LoseAMLX / S&P -79.43% / -15.69% |
| 2022-Q41/1 |
WinAMLX / S&P 31.26% / 7.56% |
No dataAMLX / S&P / 11.88% |
No dataAMLX / S&P / -17.99% |
| 2022-Q31/1 |
WinAMLX / S&P 46.16% / -4.88% |
No dataAMLX / S&P / 13.47% |
No dataAMLX / S&P / -1.41% |
| 2022-Q21/1 |
WinAMLX / S&P 49.88% / -16.10% |
No dataAMLX / S&P / 13.71% |
No dataAMLX / S&P / 11.04% |
| 2022-Q10/0 |
No dataAMLX / S&P / -4.60% |
No dataAMLX / S&P / 15.97% |
No dataAMLX / S&P / 42.23% |
| 2021-Q40/0 |
No dataAMLX / S&P / 11.03% |
No dataAMLX / S&P / 15.00% |
No dataAMLX / S&P / 96.40% |
| 2021-Q30/0 |
No dataAMLX / S&P / 0.58% |
No dataAMLX / S&P / 10.77% |
No dataAMLX / S&P / 69.42% |
| 2021-Q20/0 |
No dataAMLX / S&P / 8.55% |
No dataAMLX / S&P / 6.58% |
No dataAMLX / S&P / 51.81% |
| 2021-Q10/0 |
No dataAMLX / S&P / 6.17% |
No dataAMLX / S&P / -1.06% |
No dataAMLX / S&P / 7.39% |
| 2020-Q40/0 |
No dataAMLX / S&P / 12.15% |
No dataAMLX / S&P / -3.72% |
No dataAMLX / S&P / -33.42% |
| 2020-Q30/0 |
No dataAMLX / S&P / 8.93% |
No dataAMLX / S&P / -2.04% |
No dataAMLX / S&P / -27.10% |
| 2020-Q20/0 |
No dataAMLX / S&P / 20.54% |
No dataAMLX / S&P / -0.46% |
No dataAMLX / S&P / -27.11% |
| 2020-Q10/0 |
No dataAMLX / S&P / -19.60% |
No dataAMLX / S&P / 3.47% |
No dataAMLX / S&P / -14.75% |
| 2019-Q40/0 |
No dataAMLX / S&P / 9.07% |
No dataAMLX / S&P / 5.36% |
No dataAMLX / S&P / 2.99% |
| 2019-Q30/0 |
No dataAMLX / S&P / 1.70% |
No dataAMLX / S&P / 5.02% |
No dataAMLX / S&P / 0.21% |
| 2019-Q20/0 |
No dataAMLX / S&P / 4.30% |
No dataAMLX / S&P / 6.64% |
No dataAMLX / S&P / 8.65% |
| 2019-Q10/0 |
No dataAMLX / S&P / 13.65% |
No dataAMLX / S&P / 8.12% |
No dataAMLX / S&P / 14.29% |
| 2018-Q40/0 |
No dataAMLX / S&P / -13.52% |
No dataAMLX / S&P / 9.05% |
No dataAMLX / S&P / 18.23% |
| 2018-Q30/0 |
No dataAMLX / S&P / 7.71% |
No dataAMLX / S&P / 10.21% |
No dataAMLX / S&P / 19.06% |
| 2018-Q20/0 |
No dataAMLX / S&P / 3.43% |
No dataAMLX / S&P / 9.03% |
No dataAMLX / S&P / 14.46% |
| 2018-Q10/0 |
No dataAMLX / S&P / -0.76% |
No dataAMLX / S&P / 7.68% |
No dataAMLX / S&P / 12.46% |
| 2017-Q40/0 |
No dataAMLX / S&P / 6.64% |
No dataAMLX / S&P / 7.03% |
No dataAMLX / S&P / 13.82% |
| 2017-Q30/0 |
No dataAMLX / S&P / 4.48% |
No dataAMLX / S&P / 5.68% |
No dataAMLX / S&P / 17.57% |
| 2017-Q20/0 |
No dataAMLX / S&P / 3.09% |
No dataAMLX / S&P / 4.83% |
No dataAMLX / S&P / 17.74% |
| 2017-Q10/0 |
No dataAMLX / S&P / 6.07% |
No dataAMLX / S&P / 3.67% |
No dataAMLX / S&P / 13.32% |
| 2016-Q40/0 |
No dataAMLX / S&P / 3.82% |
No dataAMLX / S&P / 2.09% |
No dataAMLX / S&P / 7.05% |
| 2016-Q30/0 |
No dataAMLX / S&P / 3.85% |
No dataAMLX / S&P / 0.20% |
No dataAMLX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AMLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 296.38% | 20.78% |
| Annualized return | 296.38% | 20.78% |
5Y · 2022-01-07 to 2026-08-27
| Metric | AMLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 105.76% | 83.14% |
| Annualized return | 15.52% | 12.86% |
10Y · 2022-01-07 to 2026-08-27
| Metric | AMLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 105.76% | 319.30% |
| Annualized return | 7.48% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |